PatternsRadar
Sign in

AARTIDRUGSAarti Drugs Limited

NSE
Full chart
428.80INR+13.80 (+3.33%)Close · 6 Oct 2026
31 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹3,914 CrMarket cap
20.5P/E (TTM)
39.4%Delivery

Filings & corporate actions

80 results filed
CSV
Next results · Q2 FY27
Expected 20 Oct 2026 – 7 Nov 2026
Estimate: filed 20–38 days after quarter end, last 5 times
Dividend
₹2.00 per share · last 9 Feb 2026
2026
  • 31 JulresultsResults · Q1 FY27 · consolidated and standalone-3.7%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026-1.0%NSE
  • 15 MayresultsResults · Q4 FY26 · consolidated and standalone-0.5%NSE
  • 20 AprshareholdingShareholding · 31 Mar 2026-2.1%NSE
  • 9 FebdividendDividend · ₹2.00 per share+0.7%
  • 3 FebresultsResults · Q3 FY26 · consolidated and standalone-5.0%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-0.2%NSE

Reaction to results · all yearsrose on day 0 in 29 of 78 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2731 Jul 2026-3.7%0.0%-2.6%1.8×
Q4 FY2615 May 2026-0.5%+7.3%+1.0%0.9×
Q3 FY263 Feb 2026-5.0%-3.9%-7.6%8.5×
Q2 FY267 Nov 2025+5.9%-5.8%-19.1%8.9×
Q1 FY2618 Jul 2025+4.2%+0.8%-6.2%3.8×
Q4 FY256 May 2025+20.0%+32.2%+35.4%42.8×
Q3 FY2530 Jan 2025+2.8%+4.8%-6.7%1.9×
Q2 FY2524 Oct 2024-2.1%+0.6%-6.4%1.4×
Q1 FY2526 Jul 2024-4.5%-5.2%+12.8%1.9×
Q4 FY244 May 2024-2.3%-6.1%-2.8%1.1×
Q3 FY2424 Jan 2024-5.7%-4.8%-0.9%2.1×
Q2 FY2420 Oct 2023-4.9%-14.8%-12.8%1.5×
Q1 FY2422 Jul 2023+18.6%+16.5%+12.3%25.8×
Q4 FY2330 Apr 2023+8.8%+4.0%+5.0%5.0×
Q3 FY2328 Jan 2023-1.6%-3.3%-10.5%5.2×
Q2 FY2321 Oct 20220.0%+4.0%0.0%0.5×
Q1 FY2328 Jul 2022-3.2%+3.3%+3.0%3.3×
Q4 FY2210 May 2022-3.3%-2.7%-2.0%1.1×
Q3 FY221 Feb 2022-0.2%+3.8%-9.2%0.7×
Q2 FY2228 Oct 2021-5.0%-7.4%-19.2%2.2×
Q1 FY2228 Jul 2021-6.3%-7.6%-14.8%5.8×
Q4 FY2115 May 2021-8.0%-9.6%-11.2%2.0×
Q3 FY2125 Jan 2021-3.1%-4.3%-11.7%1.1×
Q2 FY2124 Oct 2020-5.0%-12.7%-6.1%1.6×
Q1 FY2125 Jul 2020+10.0%+10.1%+117.3%9.5×
Q4 FY2016 May 2020-8.0%+2.4%+16.2%3.0×
Q3 FY207 Feb 2020+0.5%+4.1%-0.3%3.0×
Q2 FY2024 Oct 2019+7.1%+8.3%+7.4%4.7×
Q1 FY2027 Jul 2019-1.0%-9.5%-5.1%1.4×
Q4 FY1916 May 2019-2.7%-6.7%-11.6%1.1×
Q3 FY1919 Feb 2019-0.3%+0.2%+12.0%0.5×
Q2 FY1923 Nov 2018+1.5%+2.8%+2.8%0.5×
Q1 FY1923 Aug 2018-0.6%+0.9%+3.8%0.3×
Q4 FY1825 May 2018-0.6%-1.5%+12.2%0.7×
Q3 FY1813 Mar 2018+1.7%-0.8%+6.3%2.8×
Q2 FY1820 Nov 2017-1.0%+2.8%+7.4%1.4×
Q1 FY1823 Aug 2017-0.2%-0.9%+1.9%0.4×
Q4 FY1727 May 2017-2.2%-2.7%+7.0%1.4×
Q3 FY179 Feb 2017+0.5%-0.3%-6.7%2.3×
Q2 FY1714 Nov 2016-4.5%-5.7%+5.9%0.4×
Q1 FY1713 Aug 2016-4.3%+0.5%+3.1%1.5×
Q4 FY1610 May 2016-0.3%+7.1%-0.4%0.6×
Q3 FY166 Feb 2016-2.2%-1.0%-0.5%1.0×
Q2 FY167 Nov 2015-5.9%-4.4%-5.4%4.1×
Q1 FY1631 Jul 2015-4.9%-7.3%-20.4%1.2×
Q4 FY1521 May 2015-6.9%-12.3%-18.0%2.6×
Q3 FY1531 Jan 2015+10.0%-0.8%+7.6%1.8×
Q2 FY1520 Nov 2014-1.5%-6.0%-4.1%0.5×
Q1 FY1513 Aug 2014+3.3%+15.7%+19.5%2.7×
Q4 FY147 May 2014-2.1%-6.6%-1.9%0.4×
Q3 FY141 Feb 2014+3.2%+0.5%+19.7%0.7×
Q2 FY1419 Nov 2013-2.1%-7.3%-9.8%1.8×
Q1 FY145 Aug 2013+0.6%+11.2%+2.2%0.6×
Q4 FY1318 May 2013+6.5%+3.2%-0.4%6.2×
Q3 FY137 Feb 20130.0%-7.5%-14.3%2.4×
Q2 FY131 Nov 2012+11.3%+26.1%+24.2%17.5×
Q1 FY1314 Aug 2012-1.7%-6.7%+12.3%0.8×
Q4 FY1226 May 2012+3.6%+3.6%+19.8%1.6×
Q3 FY122 Feb 2012-3.1%-7.0%-8.1%3.0×
Q2 FY1212 Nov 2011-1.7%-12.9%-17.5%1.3×
Q1 FY1229 Jul 2011-1.2%-10.2%-15.1%0.4×
Q4 FY1126 May 2011+2.2%+3.1%-0.9%4.8×
Q3 FY112 Feb 2011+0.3%-7.6%-4.4%0.8×
Q2 FY1129 Oct 2010+2.0%+10.8%-1.5%2.0×
Q1 FY1130 Jul 2010-6.4%0.0%+3.4%1.1×
Q4 FY1026 May 2010+2.1%+13.1%+19.7%1.1×
Q3 FY1025 Jan 2010-2.3%-3.1%-11.9%1.1×
Q2 FY1030 Oct 2009+2.1%+13.4%+11.3%0.5×
Q1 FY1030 Jul 2009+8.8%+16.9%+35.3%5.0×
Q4 FY092 Jun 20090.0%-5.2%-14.3%0.3×
Q3 FY0929 Jan 2009-10.1%-11.1%-13.1%6.1×
Q2 FY0920 Oct 2008-3.2%-4.3%-4.3%0.7×
Q1 FY0928 Jul 2008+7.4%+9.9%+12.4%5.4×
Q4 FY0813 May 2008-0.8%0.0%-9.2%1.3×
Q3 FY0828 Jan 2008+3.2%+3.9%+3.2%0.7×
Q2 FY0830 Oct 2007+0.6%+1.1%+5.7%0.4×
Q1 FY0830 Jul 2007-1.8%+8.4%+6.6%0.6×
Q4 FY0718 May 2007+0.6%-4.5%+21.6%1.6×
Average+0.0%+0.2%+1.9%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY—
Profit YoY—
Interest cost YoY—
Revenue QoQ-2.4%
Profit QoQ-9.3%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+4.4%-0.9%—+4.1%+5.5%+7.7%
Profit+3.7%+2.1%—-4.8%-1.1%+11.6%

Key data

CSV
Open421.15
Day range414.10 – 430.25
52-week range318.95 – 534.00
From 52w high-19.7%
RSI (14)52.2
ATR (14)15.12
Volume1.33L
Avg volume (20D)1.90L
Rel volume0.70×
Volatility (1Y)30.7%
Turnover₹5.7Cr
SMA 50 / 200422.01 / 388.60

Delivery percentage

Latest · 6 Oct 202639.4%
20-day avg47.8%
1-year avg50.1%
Percentile (own history)33rd
Range2.0–100.0%
Sessions1,731

Over the last 20 sessions AARTIDRUGS settled 47.8% of its traded quantity, which is above average for an NSE equity. Its one-year average is 50.1%, so recent sessions are running 2.3 points lower than usual. The latest session ranks higher than 33% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.33%-0.20%+0.69%+10.25%+21.58%-8.76%

Valuation

CSV
Market cap₹3,914 Cr
P/E (TTM)20.5
EPS (TTM)20.94
Shares outstanding9.13Cr
Listed19 Sept 2003

Ownership

CSV
Promoter54.43%
Promoter Δ QoQ-0.60 pp
Public45.57%
FII1.52%
DII10.29%
Pledged2.50%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)652.8601.7720.3702.8
YoY chg+9.1%+8.1%+6.4%+19.0%
Net profit (₹ Cr)45.240.655.350.1
YoY chg+29.2%+9.3%-12.0%-7.1%
Net margin6.9%6.7%7.7%7.1%
EPS4.954.446.055.49

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 54.43% · public 45.57%
30 Sept 2021: promoter 60.12%31 Dec 2021: promoter 59.99%31 Mar 2022: promoter 59.83%30 Jun 2022: promoter 59.98%30 Sept 2022: promoter 59.77%31 Dec 2022: promoter 59.66%31 Mar 2023: promoter 59.58%30 Jun 2023: promoter 58.70%30 Sept 2023: promoter 58.56%31 Dec 2023: promoter 57.47%31 Mar 2024: promoter 57.13%30 Jun 2024: promoter 55.67%30 Sept 2024: promoter 55.64%31 Dec 2024: promoter 55.38%31 Mar 2025: promoter 55.48%30 Jun 2025: promoter 55.22%30 Sept 2025: promoter 54.72%31 Dec 2025: promoter 55.03%31 Mar 2026: promoter 55.03%30 Jun 2026: promoter 54.43%
2021-092026-06
  • Promoter
  • Public and others
Promoter
54.43%
Public
45.57%
Promoter change
-0.60 pp
Filed
20 Jul 2026
FII
1.52%
DII
10.29%
Promoter pledged
2.50%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24AQ3 FY24AQ4 FY24AQ1 FY25AQ2 FY25AQ3 FY25AQ4 FY25AQ1 FY26AQ2 FY26AQ3 FY26AQ4 FY26AQ1 FY27A
Revenue from operations641.5605.9620.0590.5598.3556.6676.8590.5652.8601.7720.3702.8
Other income0.71.71.10.31.511.91.90.30.11.20.80.8
Total income642.2607.6621.1590.8599.8568.5678.6590.8652.9602.9721.1703.6
Total expenses586.0556.1556.9539.7553.9517.7607.5539.7592.5573.9650.7632.3
└ Finance costs8.37.69.18.68.99.19.28.67.79.38.29.2
└ Depreciation12.612.713.614.713.713.814.914.716.318.018.018.5
Profit before tax56.351.664.251.145.950.871.251.160.429.070.469.2
Tax expense16.714.816.9(2.9)10.913.78.4(2.9)15.3(11.5)15.119.1
Net profit39.636.747.354.035.037.162.854.045.240.655.350.1
EPS4.293.995.155.913.834.066.885.914.954.446.055.49
Net margin6.17%6.06%7.63%9.14%5.84%6.66%9.28%9.14%6.92%6.74%7.67%7.13%
PBT margin8.77%8.51%10.35%8.66%7.67%9.12%10.51%8.66%9.25%4.82%9.77%9.85%
Tax rate29.63%28.79%26.29%-5.60%23.80%26.93%11.78%-5.60%25.24%-39.73%21.46%27.60%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.

AARTIDRUGS at a glance

  • AARTIDRUGS closed at ₹428.8 on 6 Oct 2026, +3.33% on the day, -8.8% over one year, 19.7% below its 52-week high of ₹534.
  • Delivery was 39.4% of traded quantity on 6 Oct 2026, the 33rd percentile of its own 1,731 sessions with a reading (20-session average 47.8%, 1-year average 50.1%).
  • Market capitalisation is ₹3,914 crore at a trailing P/E of 20.5 (trailing EPS ₹20.94).
  • Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹703 crore (+19.0% year on year), net profit ₹50 crore (-7.1%); the price moved -3.7% on the first session after.
  • Promoters held 54.43% at 30 Jun 2026, down 0.60 percentage points on the previous filing, with 2.50% of promoter shares pledged.
  • Q2 FY27 results are expected between 20 Oct 2026 and 7 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE767A01016
SeriesEQ
Listed19 Sept 2003
History from19 Sept 2003
Sessions5,719

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE